di-nitrophenylcarboxamide | 19613-80-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: di-nitrophenylcarboxamide
• 英文别名: 2,3-dinitrobenzamide；dinitrobenzamide；2,3-Dinitro-benzamid；2.3-Dinitro-benzamid
• CAS: 19613-80-0
• 化学式: C₇H₅N₃O₅
• 分子量: 211.134
• InChiKey: KIMCGLHTSSZPNS-UHFFFAOYSA-N

物化性质

• 沸点：
  355.3±22.0 °C(Predicted)
• 密度：
  1.601±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  di-nitrophenylcarboxamide 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.32 kPa 条件下， 反应 16.0h， 以79%的产率得到2,3-二氨基苯甲酰胺
  参考文献：
  名称：

  Checkpoint Kinase Inhibitors:  SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles

  摘要：

  The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenzimidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.

  DOI：

  10.1021/jm0495935
• 作为产物：
  描述：

  2,3-二硝基苯甲酸 在 ammonium carbonate 、 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 以42%的产率得到di-nitrophenylcarboxamide
  参考文献：
  名称：

  Checkpoint Kinase Inhibitors:  SAR and Radioprotective Properties of a Series of 2-Arylbenzimidazoles

  摘要：

  The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenzimidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.

  DOI：

  10.1021/jm0495935

文献信息

• [EN] NITROANILINE-BASED ALKYLATING AGENTS AND THEIR USE AS PRODRUGS<br/>[FR] AGENTS D'ALKYLATION A BASE DE NITROANILINE ET LEUR UTILISATION EN TANT QUE PROMEDICAMENTS
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2004033415A1

  公开（公告）日：2004-04-22

  Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as produgs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjuction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents.

  基于硝基苯胺的不对称芥末化合物，其通用公式为（I），以及它们的制备方法和使用方法，作为基因依赖性酶前药治疗（GDEPT）和与硝基还原酶酶结合的细胞消融治疗的药物，以及作为缺氧选择性细胞毒素和抗癌药物的使用方法。
• [EN] NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA TUBERCULOSE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019034729A1

  公开（公告）日：2019-02-21

  The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

  这项发明涉及到式（I）的化合物或其药用盐以及它们在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病，如结核病。
• [EN] NITROPHENYL MUSTARD ALCOHOLS, THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS<br/>[FR] ALCOOLS DE MOUTARDE NITROPHÉNYLES, LEURS PHOSPHATES CORRESPONDANTS ET LEUR UTILISATION EN TANT QU'AGENTS CYTOTOXIQUES CIBLÉS
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2010044685A1

  公开（公告）日：2010-04-22

  The invention provides nitrophenyl mustard compounds useful in cancer therapy as targeted cytotoxic agents, of Formula (I) and Formula (II): wherein X represents C1, Br, I, or OSO2R1, Y represents C1, Br, I, or OSO2R1, Z represents at any available ring position -CO- or -SO2-, R represents: (1) a straight or branched chain C1-6 alkyl group or -CH2CH2OMe, when X and Y are the same, or (2) a straight or branched chain C3-6 alkyl group or -CH2CH2OMe when X and Y are different, R1 represents a straight or branched chain C1-6 alkyl group, and n is an integer from 1 to 6; and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, comprising the compounds of Formula (I) and (II), and methods of treating cancer by administration of the compounds.

  该发明提供了一种在癌症治疗中作为靶向细胞毒性剂使用的硝基苯芥类化合物，其化学式为(I)和(II)：其中X代表C1、Br、I或OSO2R1，Y代表C1、Br、I或OSO2R1，Z代表任何可用的环位置上的-CO-或-SO2-，R代表：(1)当X和Y相同时，为直链或支链C1-6烷基或-CH2CH2OMe，或者(2)当X和Y不同时，为直链或支链C3-6烷基或-CH2CH2OMe，R1代表直链或支链C1-6烷基，n为1至6的整数；以及其药学上可接受的盐。还提供了包含化合物(I)和(II)的药物组合物，以及通过给药这些化合物来治疗癌症的方法。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019034702A1

  公开（公告）日：2019-02-21

  The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis

  这项发明涉及到式（I）化合物及其在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病，如结核病。
• [EN] PROBES FOR RAPID AND SPECIFIC DETECTION OF MYCOBACTERIA<br/>[FR] SONDES POUR LA DÉTECTION RAPIDE ET SPÉCIFIQUE DE MYCOBACTÉRIES
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017027062A1

  公开（公告）日：2017-02-16

  The compositions of the present disclosure provide novel fluorogenic probes for use in the specific imaging and detection of mycobacteria species, and in particular β-lactam- antibiotic resistant. Specificity for mycobacteria is conferred on these probes by incorporating a moiety that specifically targets the unique trapping mechanism of the DprE1 found in in mycobacteria. Accordingly, only Mycobacteria species that express both a β- lactamase and DprE1 enable both the activation of the caged fluorescent probe, and the affixing of the released fluorescent probes to the bacteria cells through the functioning reduction-covalent binding mechanism. Advantageously, such a probe is able, at its most sensitive, to allow single mycobacterium detection.

  本公开的组成提供了新颖的生色团探针，用于特定地成像和检测分枝杆菌种类，尤其是对β-内酰胺类抗生素具有抗药性的种类。这些探针通过引入一种特定针对分枝杆菌中DprE1独特捕获机制的基团，从而实现对分枝杆菌的特异性。因此，只有表达β-内酰胺酶和DprE1的分枝杆菌种类才能激活笼状荧光探针，并通过功能性还原-共价结合机制将释放的荧光探针固定到细菌细胞上。这种探针的一个显著优点是，在其最敏感的情况下，能够实现单个分枝杆菌的检测。